PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.

about

PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study.

Item

http://www.wikidata.org/entity/Q47203358

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@en

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@nl

type

Item

label

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@en

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@nl

prefLabel

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@en

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@nl

P1476

PSA response to cabazitaxel is ...... interventional QoLiTime study.

@en

P2093

Christine Windemuth-Kieselbach

http://www.w3.org/2001/XMLSchema#string

Martin Keller

http://www.w3.org/2001/XMLSchema#string

Peter Hammerer

http://www.w3.org/2001/XMLSchema#string

Ralf-Dieter Hofheinz

http://www.w3.org/2001/XMLSchema#string

Salah-Eddin Al-Batran

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Update on tubulin-binding agents.

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.

Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

P2888

s00345-017-2138-x

P31

scholarly article

P356

10.1007/S00345-017-2138-X

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29305637

http://www.w3.org/2001/XMLSchema#string